dc.creatorMoscoso J., Felipe
dc.creatorQuera P., Rodrigo
dc.date.accessioned2019-03-18T11:54:14Z
dc.date.available2019-03-18T11:54:14Z
dc.date.created2019-03-18T11:54:14Z
dc.date.issued2016
dc.identifierRevista Medica de Chile, Volumen 144, Issue 2, 2018, Pages 211-221
dc.identifier07176163
dc.identifier00349887
dc.identifier10.4067/S0034-98872016000200010
dc.identifierhttps://repositorio.uchile.cl/handle/2250/166767
dc.description.abstract© 2016, Sociedad Medica de Santiago. All rights reserved.The prevalence of Celiac disease in the general population is approximately 1% and remains undiagnosed in a significant proportion of individuals. Its clinical presentation includes the classical malabsorption syndrome, unspecific and extra-intestinal manifestations, and silent celiac disease. The serologic diagnosis has an elevated sensitivity and specificity and, at least in adult population, it must be confirmed by biopsy in every case. Diagnosis in subjects already on gluten free diet includes HLA typing and gluten challenge with posterior serologic and histologic evaluation. The core of the treatment is the gluten free diet, which must be supervised by an expert nutritionist. Monitoring must be performed with serology beginning at 3-6 months, and with histology two years after the diagnosis, unless the clinical response is poor. Poor disease control is associated with complications such as lymphoma and small bowel adenocarci
dc.languageen
dc.publisherSociedad Medica de Santiago
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceRevista Medica de Chile
dc.subjectAutoimmunity
dc.subjectCeliac disease
dc.subjectDiet
dc.subjectGluten free
dc.subjectGlutens
dc.subjectMalabsorption syndromes
dc.titleUpdate on celiac disease Enfermedad celíaca. revisión
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución